At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
AZD3241 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy
In Brief
A Phase 2 clinical trial evaluating AZD3241 and Placebo for Multiple System Atrophy, MSA. Completed, enrolled 59 participants across 17 sites in 7 countries.
Detailed Summary
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple System Atrophy, MSA
CountriesAustria, Finland, France, Italy, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartApr 2015
Primary CompletionSep 2016
TodayJul 2026
First PostedMar 17, 2015
Enrollment StartApr 27, 2015
Primary CompletionSep 19, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.3 years ago
Interventions
AZD3241drug
Drug: AZD3241 administered for 12 weeks orally as a tablet.
Placebodrug
Placebo to match AZD3241 administered for 12 weeks orally as a tablet.